Not long ago, I attended a webinar on regenerative medicine. The speaker was the sort of polished, confident expert you expect at these events. During the Q&A, someone finally asked the question that always comes up: Does insurance cover any of this?

The answer was a flat no. Cash only. And not a small sum, either. A number that made even me, after decades in medicine and not easily shocked by price tags, raise an eyebrow.

What caught my attention wasn’t the price itself, but the reasoning behind it. The presenter made a strong case that his approach, more sophisticated, more individualized, justified the higher fee. I can appreciate that argument. But he didn’t provide any data showing his outcomes were better than what patients receive through standard, insurance-based care. The unspoken message seemed to be: Pay more, get a better result. No one in the audience questioned it, and I doubt he intended to mislead. Still, the difference between “individualized and sophisticated” and “clinically superior” is where cash-pay medicine gets ethically complicated. It’s a conversation we, as a profession, don’t have often or openly enough.

That evening sent me back to a question worth asking directly: Does paying cash change the standard of care, or only the story we tell ourselves?

I sometimes call this the first-class ticket problem. When I buy a first-class seat, I expect better food, more legroom, maybe even a smile from the flight attendant. But if I’m honest, there’s a small, irrational part of me that thinks if something goes wrong (say, an emergency landing or heavy turbulence), I’ll somehow be better off up front. I’ve never actually read the fine print on what that ticket covers. I just assume it’s more than it probably is.

I see the same thinking in patients who pay cash for medical care. On the surface, it’s reasonable: They expect more attention, more tailored planning, and a doctor who isn’t watching the clock for the next insurance-driven appointment. But underneath, there’s often the same quiet leap I make on an airplane. The belief that paying more buys a better outcome, maybe even a better shot if things don’t go as planned. And, just like me with my first-class ticket, most patients never really ask what their payment actually covers.

Patients who pay cash often come in with an unspoken expectation: If I’m paying you directly, you’d better get this right. There’s no insurer, no claims adjuster, no bureaucracy to share the blame if things go sideways: just the patient, the doctor, and the money. That simplicity is part of what draws people to cash-based medicine, but it’s also where the ethical challenges start. Medicine has never come with a warranty, no matter how you pay. Whether I’m working with insurance or cash, the standard of care and biology’s unpredictability remain the same. Paying cash doesn’t change how the body heals, and it shouldn’t change the promises we make as physicians.

Still, the language we use (words like “personalized,” “concierge,” or “advanced technology”) can easily give the impression that money buys certainty. Patients hear “premium” and think it means “guaranteed.” The problem isn’t that anyone is lying; it’s that we don’t always step in to correct the assumption.

Let’s go back to that webinar for a moment, because it highlights the issue perfectly. “Individualized” and “sophisticated” care can absolutely improve a patient’s experience. But those qualities alone don’t prove better outcomes. For that, we need data: comparisons, follow-up rates, complication rates, something to measure against standard care. Without that, suggesting superiority based on price or new technology is just marketing dressed up as medicine.

This isn’t about bad intentions. Most doctors who build cash-pay practices around advanced techniques truly believe in what they’re offering. I know the feeling; enthusiasm is not the same as deception. But belief isn’t evidence. When a roomful of patients hears a confident, well-credentialed physician talk up his own results, they’ll fill in the blanks themselves. If no one asks, “Compared to what? Measured how?” then the silence becomes its own answer. That’s the real risk, not outright dishonesty, but the assumptions we leave unchallenged.

Ironically, the presenter seemed to understand this principle, at least when it came to everyone else. He encouraged the physicians in the audience to use follow-up questionnaires and track outcomes, bringing real data to future patient conversations. That’s good advice; tracking outcomes is what separates marketing from medicine. Yet when it came to his own results, he offered stories, anecdotes, not numbers. He was asking others to meet a standard he hadn’t applied to himself.

Taking the insurer out of the equation doesn’t just cut down on paperwork. It also removes a layer of oversight. Utilization reviews and medical-necessity checks aren’t perfect, but they do provide some outside scrutiny of our decisions. In a cash arrangement, that oversight is gone. Now it’s just the doctor and the patient, with no one else checking if the treatment is appropriate, fairly priced, or clearly explained.

If we don’t make transparency a priority, no one else will. Cash-pay medicine doesn’t get a pass on ethics just because there’s no third party involved. If anything, it raises the bar, because the only safeguard left is our own integrity.

Standard informed consent covers risks, benefits, and alternatives. A cash-pay practice should go further:

• Expected versus guaranteed outcomes: State plainly that payment secures access to evaluation and treatment, not a specific result.
• What the evidence actually supports: If a treatment is marketed as advanced, say whether comparative outcome data exists, and if it doesn’t, say that too. Paying for a superior experience and paying for a proven superior result are different purchases.
• What happens if the outcome isn’t achieved: A revision policy, a partial refund, or neither: Silence here isn’t neutral; it invites the patient to assume whatever is most favorable, and that assumption curdles into resentment later.
• What cash does and doesn’t cover if complications arise: Stated before treatment, not while the patient is in a recovery gown asking why a new bill appeared.
• How disputes get resolved: Whether mediation, a second-opinion referral, or a formal pathway, rather than leaving the patient to escalate out of frustration.

None of this is just paperwork for its own sake. It’s an ethical responsibility, put into words a patient can actually understand. The fine print on the ticket, finally handed over instead of left in the drawer.

Cash-pay medicine can create more trust between doctor and patient, simply because there’s no one else in the room. That trust is valuable, and it’s worth protecting. But if it’s built on the unspoken promise of guaranteed results, it’s a shaky foundation.

Physicians who choose the cash-pay model aren’t wrong. There are real advantages: simpler billing, more freedom from insurance-driven protocols. But those benefits come with a responsibility; we have to provide the clarity and transparency that the old system, for all its faults, at least tried to offer.

The physician at that webinar is clearly skilled and likely gets good results. But I have no way of knowing for sure, and neither did anyone else listening. That’s the heart of the issue. If we’re going to ask patients to trust us more directly, and pay us more directly for that trust, we owe them more directness and transparency in return.

Francisco M. Torres is an interventional physiatrist specializing in diagnosing and treating patients with spine-related pain syndromes. He is certified by the American Board of Physical Medicine and Rehabilitation and the American Board of Pain Medicine and can be reached at Florida Spine Institute and Wellness. 

Dr. Torres was born in Spain and grew up in Puerto Rico. He graduated from the University of Puerto Rico School of Medicine. Dr. Torres performed his physical medicine and rehabilitation residency at the Veterans Administration Hospital in San Juan before completing a musculoskeletal fellowship at Louisiana State University Medical Center in New Orleans. He served three years as a clinical instructor of medicine and assistant professor at LSU before joining Florida Spine Institute in Clearwater, Florida, where he is the medical director of the Wellness Program.

Dr. Torres is an interventional physiatrist specializing in diagnosing and treating patients with spine-related pain syndromes. He is certified by the American Board of Physical Medicine and Rehabilitation and the American Board of Pain Medicine. He is a prolific writer and primarily interested in preventative medicine. He works with all of his patients to promote overall wellness.